According to the instructions for appointment of the nomination committee for
The nomination committee has had its first meeting where the composition of the nomination committee has been determined.
The nomination committee ahead of the AGM 2022 consists of the following members:
- Malin Björkmo, chairman of the nomination committee, appointed by Handelsbanken Fonder representing approximately 3.68 percent of the shares and votes,
Lars Lind , appointed byHans Enocson representing approximately 2.82 percent of the shares and votes,Ulrik Grönvall , appointed bySwedbank Robur Fonder which represents about 2.59 percent of the shares and votes, and- Pär-Ola Mannefred, chairman of the board of
Isofol Medical AB (publ)
In addition, representatives of minority owners who represent approximately 12.51 percent of votes and shares have appointed Matsola Palm.
The members of the nomination committee are appointed by owners who represent a total of about 21.60 percent of the total number of shares and votes in
Information about the nomination committee's work and the instructions to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee's proposal will be presented in the summon to the annual general meeting 2022 and on the company's website, www.isofolmedical.com.
Shareholders who wish to submit proposals to the nomination committee shall do this in writing by sending an e-mail to valberedningen@isofolmedical.com (heading: "Isofol's nomination committee") or by mail to the following address:
Att. Valberedningen
Arvid Wallgrens Backe 20
413 46 GOTHENBURG
Any proposals must be received by the nomination committee no later than
For more information, please contact
Pär-Ola Mannefred, chairman of the board
E-mail: par-ola.mannefred@residenset.se
Ulf Jungnelius, M.D., CEO
E-mail: jungnelius@isofolmedical.com
Telephone: +46 709-16 89 55
The information was submitted for publication, through the agency of the contact person set out above, at
About arfolitixorin
Arfolitixorin is Isofol's proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global pivotal Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit more patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.
About Isofol Medical AB (publ)
www.isofolmedical.com
https://news.cision.com/isofol-medical-ab--publ-/r/isofol-appoints-nomination-committee-ahead-of-the-annual-general-meeting-2022,c3457068
https://mb.cision.com/Main/15598/3457068/1498912.pdf
(c) 2021 Cision. All rights reserved., source